Patents Assigned to Peloton Therapeutics, Inc.
  • CD73 inhibitors and uses thereof
    Patent number: 11591355
    Abstract: The present disclosure provides compounds of Formula (II) wherein R1, R2, R3, R4, R5, W1, W2, W3, X, Y, and A are as described herein. The disclosed compounds modulate CD73 activity. The present disclosure also provides, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: February 28, 2023
    Assignee: Peloton Therapeutics Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
  • PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS
    Publication number: 20220162193
    Abstract: Compounds of formula I, that induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity are described herein.
    Type: Application
    Filed: April 6, 2020
    Publication date: May 26, 2022
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Michelle Ann Estrada, Jonas Grina, Paul Wehn, Rui Xu
  • METHODS OF PREPARING SUBSTITUTED INDANES
    Publication number: 20220081407
    Abstract: This application discloses methods for the synthesis of substituted indane analogs that modulate HIF-2? activity, as well as key intermediates produced thereby. The synthesis of 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile was exemplified.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 17, 2022
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Peter J. Stengel, Rui Xu, Stacey Renee Spencer
  • SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SUBSTITUTED INDANE AND METHODS FOR THE PREPARATION AND USE THEREOF
    Publication number: 20210387946
    Abstract: Provided herein are solid dispersions comprising a HIF-2? inhibitor, pharmaceutical compositions comprising the solid dispersions, and methods for treating HIF-2?-mediated diseases and conditions.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 16, 2021
    Applicant: Peloton Therapeutics Inc.
    Inventors: Christopher Lindemann, Peter J. Stengel
  • CD73 INHIBITORS AND USES THEREOF
    Publication number: 20210317150
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 14, 2021
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
  • COMPOSITIONS AND METHODS FOR INHIBITING CD73
    Publication number: 20210253614
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 19, 2021
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Bin Wang, Hanbiao Yang, Karl Bedke, James P. Rizzi, Heli Huang, Keshi Wang
  • METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA
    Publication number: 20210015764
    Abstract: The present disclosure provides methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease. Compositions for use in these methods are also provided.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 21, 2021
    Applicant: Peloton Therapeutics Inc.
    Inventors: John A. Josey, Rajeev Shrimali, Eli M. Wallace, Tai Wong
  • Aromatic compounds and uses thereof
    Patent number: 10807948
    Abstract: Disclosed herein are substituted indane derivatives useful as HIF-2? inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2? activity are also disclosed.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 20, 2020
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Combination therapy of a HIF-2-? inhibitor and an immunotherapeutic agent and uses thereof
    Patent number: 10786480
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: September 29, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • ARYL ETHERS AND USES THEREOF
    Publication number: 20200190031
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: 10597366
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
    Patent number: 10335388
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 2, 2019
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • Compositions for use in treating pulmonary arterial hypertension
    Patent number: 10278942
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 7, 2019
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Xinlin Du, Barry Goggin
  • Compositions for Use in Treating Pulmonary Arterial Hypertension
    Publication number: 20190015377
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 17, 2019
    Applicant: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Substituted pyridines and uses thereof
    Patent number: 10155726
    Abstract: Substituted pyridines that modulate HIF-2a activity, pharmaceutical compositions containing the substituted pyridines, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2a activity are described herein.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 18, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: 10144711
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 4, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Benzimidazole derivatives and uses thereof
    Patent number: 10040767
    Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: August 7, 2018
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Hanbiao Yang
  • COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF
    Publication number: 20180140569
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.
    Type: Application
    Filed: April 14, 2016
    Publication date: May 24, 2018
    Applicant: Peloton Therapeutics, Inc.
    Inventors: John A. JOSEY, Eli M. WALLACE, Guangzhou HAN
  • Aryl ethers and uses thereof
    Patent number: 9969689
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: May 15, 2018
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Aryl ethers and uses thereof
    Patent number: RE49948
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: April 30, 2024
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang